TSCAN THERAPEUTICS INC. - COMMON STOCK

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

07 12 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

04 12 2023 16:05:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

04 12 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

30 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

09 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

06 11 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

02 11 2023 09:05:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

27 9 2023 09:06:51 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME

29 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

10 8 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces Transition of Chief Financial Officer

29 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

06 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

01 6 2023 16:10:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces Closing of Public Offering

01 6 2023 16:05:35 提供 Nasdaq GlobeNewswire

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

01 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces Pricing of $140 Million Public Offering

26 5 2023 00:37:03 提供 Nasdaq GlobeNewswire

TScan Therapeutics Announces Launch of Proposed Public Offering

25 5 2023 16:06:50 提供 Nasdaq GlobeNewswire

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

24 5 2023 16:13:47 提供 Nasdaq GlobeNewswire

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

17 5 2023 07:00:00 提供 Nasdaq GlobeNewswire

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

10 5 2023 07:00:01 提供 Nasdaq GlobeNewswire